
Press release



IBA and RaySearch join forces to advance adaptive proton therapy

IBA and RaySearch announce strategic alliance to offer a unique integrated comprehensive solution for adaptive proton radiation therapy

Louvain-la-Neuve, Belgium, and Stockholm, Sweden, September 5, 2016 – IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer and RaySearch Laboratories, the global leader in treatment planning software, have entered into a long-term strategic alliance to combine their respective technologies and advance adaptive proton therapy.

As part of the collaboration, the RayCare® oncology information system, which is currently in development at RaySearch, will be customized for optimal use together with the IBA delivery solutions. In both RayStation and RayCare, as well as in the IBA delivery solutions, joint features, dedicated software interfaces and modified graphical user interface components will allow for a close and seamless workflow integration with optimized performances. The result will be a complete turnkey solution for all software and hardware needed to deliver outstanding adaptive proton therapy treatment.

Proton therapy is one of the most precise forms of radiation therapy: targets can be pinpointed with the optimal radiation dose, while adjacent tissue is spared to a much higher degree than with conventional radiation therapy. The technique is growing in popularity worldwide and studies are converging to point towards the fact that approximately 20% of radiation therapy patients could benefit from proton therapy while only 1% receive it today.

Johan Löf, Chief Executive Officer of RaySearch Laboratories, says: "IBA and RaySearch are committed to taking proton therapy to new levels. Through this collaboration with the world leader in proton therapy, we are giving clinics a complete platform that will optimize workflows and enable more precise and personalized treatment for patients. This will make it possible to realize the full potential of proton therapy."

Olivier Legrain, Chief Executive Officer of IBA, said: "We are certain that proton therapy will improve care for an increasing percentage of cancer patients in the coming years. By combining IBA systems with RayCare and RayStation, we are creating what we see as the most comprehensive and innovative proton therapy solution available. This alliance is an important step toward adaptive proton therapy treatment that will broaden the spectrum of clinical application and enable the best possible result for cancer patients worldwide."

END


About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,300 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Press release | September 5, 2016

Press release



More information can be found at: www.iba-worldwide.com.

About RayStation

RayStation integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

About RayCare

RayCare is a next generation OIS developed from the ground up by RaySearch to support the complex logistical challenges in modern, large-scale radiation therapy centers. RayCare integrates the high performance radiation therapy algorithms available in RayStation and adds advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. The system is expected to be released in 2017.

About RaySearch

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and which will be launched in 2017. RaySearch's software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.

More information about RaySearch is available at www.raysearchlabs.com

For further information please contact:

IBA

Bao Nguyen
Marketing Manager Proton Therapy
+32 10 203 374
bao.nguyen@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com

RaySearch

Johan Löf
President and CEO
+46 8 510 530 00
johan.lof@raysearchlabs.com